|
[1] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.
|
|
[2] RYERSON AB,EHEMAN CR,ALTEKRUSE SF,et al. Annual Report to the Nation on the Status of Cancer,1975-2012,featuring the increasing incidence of liver cancer[J]. Cancer,2016,122(9):1312-1337.
|
|
[3] MCGLYNN KA,PETRICK JL,LONDON WT. Global epidemiology of hepatocellular carcinoma:An emphasis on demographic and regional variability[J]. Clin Liver Dis,2015,19(2):223-238.
|
|
[4] LLOVET JM,RICCI S,MAZZAFERRO V,et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390.
|
|
[5] CHENG AL,KANG YK,CHEN Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised,doubleblind,placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34.
|
|
[6] CHENG AL,KANG YK,LIN DY,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer:Results of a randomized phase III trial[J]. J Clin Oncol,2013,31(32):4067-4075.
|
|
[7] JOHNSON PJ,QIN S,PARK JW,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:Results from the randomized phase III BRISK-FL study[J]. J Clin Oncol,2013,31(28):3517-3524.
|
|
[8] ZHU AX,ROSMORDUC O,EVANS TR,et al. SEARCH:A phase III,randomized,double-blind,placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2015,33(6):559-566.
|
|
[9] CAINAP C,QIN S,HUANG WT,et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma:Results of a randomized phase III trial[J]. J Clin Oncol,2015,33(2):172-179.
|
|
[10] VILGRAIN V,PEREIRA H,ASSENAT E,et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH):An open-label randomised controlled phase 3 trial[J]. Lancet Oncol,2017,18(12):1624-1636.
|
|
[11] KUDO M,UESHIMA K,YOKOSUKA O,et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS):A randomised,open label,phase 3 trial[J]. Lancet Gastroenterol Hepatol,2018,3(6):424-432.
|
|
[12] CHOW P,GANDHI M,TAN SB,et al. SIRveNIB:Selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J]. J Clin Oncol,2018,36(19):1913-1921.
|
|
[13] ABOU-ALFA GK,QIN S,RYOO BY,et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma[J]. Ann Oncol,2018,29(6):1402-1408.
|
|
[14] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[15] IKEDA K,KUDO M,KAWAZOE S,et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol,2017,52(4):512-519.
|
|
[16] WILHELM SM,DUMAS J,ADNANE L,et al. Regorafenib(BAY73-4506):A new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer,2011,129(1):245-255.
|
|
[17] ABOU-ELKACEM L,ARNS S,BRIX G,et al. Regorafenib inhibits growth,angiogenesis,and metastasis in a highly aggressive,orthotopic colon cancer model[J]. Mol Cancer Ther,2013,12(7):1322-1331.
|
|
[18] BRUIX J,QIN S,MERLE P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):A randomised,double-blind,placebo-concrolled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
|
|
[19] XIANG Q,CHEN W,REN M,et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET[J]. Clin Cancer Res,2014,20(11):2959-2970.
|
|
[20] YAKES FM,CHEN J,TAN J,et al. Cabozantinib(XL184),a novel MET and VEGFR2 inhibitor,simultaneously suppresses metastasis,angiogenesis,and tumor growth[J]. Mol Cancer Ther,2011,10(12):2298-2308.
|
|
[21] ABOU-ALFA GK,MEYER T,CHENG AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1):54-63.
|
|
[22] SPRATLIN JL,COHEN RB,EADENS M,et al. Phase I pharmacologic and biologic study of ramucirumab(IMC-1121B),a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2[J]. J Clin Oncol,2010,28(5):780-787.
|
|
[23] ZHU AX,FINN RS,MULCAHY M,et al. A phase II and biomarker study of ramucirumab,a human monoclonal antibody targeting the VEGF receptor-2,as first-line monotherapy in patients with advanced hepatocellular cancer[J]. Clin Cancer Res,2013,19(23):6614-6623.
|
|
[24] ZHU AX,PARK JO,RYOO BY,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH):A randomised,double-blind,multicentre,phase 3 trial[J]. Lancet Oncol,2015,16(7):859-870.
|
|
[25] KUDO M,HATANO E,OHKAWA S,et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma:Japanese subgroup analysis of the REACH trial[J]. J Gastroenterol,2017,52(4):494-503.
|
|
[26] PARK JO,RYOO BY,YEN CJ,et al. Second-line ramucirumab therapy for advanced hepatocellular carcinoma(REACH):An East Asian and non-East Asian subgroup analysis[J]. Oncotarget,2016,7(46):75482-75491.
|
|
[27] ZHU AX,KANG YK,YEN CJ,et al. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib(REACH-2):A randomised,double-blind,placebocontrolled phase 3 trial[J]. Lancet Oncol,2019.[Online ahead of print]
|
|
[28] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
|
[29] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
|
|
[30] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.
|
|
[31] DUFFY AG,ULAHANNAN SV,MAKOROVA-RUSHER O,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol,2017,66(3):545-551.
|
|
[32] MO H,HUANG J,XU J,et al. Safety,anti-tumour activity,and pharmacokinetics of fixed-dose SHR-1210,an anti-PD-1 antibody in advanced solid tumours:A dose-escalation,phase 1study[J]. Br J Cancer,2018,119(5):538-545.
|
|
[33] FANG W,YANG Y,MA Y,et al. Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:Results from two single-arm,phase 1 trials[J]. Lancet Oncol,2018,19(10):1338-1350.
|
|
[34] QIN S,REN Z,MENG Z,et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma:A multicentre,open-label,parallel-group,randomised,phase 2trial[J]. Lancet Oncol,2020,21(4):571-580.
|
|
[35] QIN S,FINN RS,KUDO M,et al. RATIONALE 301 study:Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma[J]. Future Oncol,2019,15(16):1811-1822.
|
|
[36] STEIN S,PISHVAIAN MJ,LEE MS,et al. Safety and clinical activity of 1L atezolizumab+bevacizumab in a phase Ib study in hepatocellular carcinoma(HCC)[J]. J Clin Oncol,2018.[Online ahead of print]
|
|
[37] FINN RS,QIN S,IKEDA M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.
|
|
[38] KASEB AO,MORRIS JS,IWASAKI M,et al. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma[J]. Onco Targets Ther,2016,9:773-780.
|
|
[39] HE L,DENG H,LEI J,et al. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma:A single-arm meta-analysis based on prospective studies[J]. BMC Cancer,2019,19(1):276.
|
|
[40] MAKKER V,RASCO D,VOGELZANG NJ,et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer:An interim analysis of a multicentre,open-label,single-arm,phase 2 trial[J]. Lancet Oncol,2019,20(5):711-718.
|
|
[41] HERBST RS,ARKENAU HT,SANTANA-DAVILA R,et al.Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer,gastro-oesophageal cancer,or urothelial carcinomas(JVDF):A multicohort,non-randomised,open-label,phase 1a/b trial[J].Lancet Oncol,2019,20(8):1109-1123.
|
DownLoad: